OrbiMed’s Merck MRK Stock Holding History

OrbiMed’s Portfolio MRK Stock Details MRK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	–	Sell	-366,800	Closed	-$21.8M	–	137
2016 Q3	$21.8M	Buy	+366,800	New	+$21.4M	0.25%	71

Other funds holding MRK

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

OrbiMed's MRK Position: Q2 2026 in Review

OrbiMed held its Merck (MRK) position steady in Q2 2026 at 663,400 shares worth $85.2M. The position accounts for 1.58% of the portfolio, ranked #13.

OrbiMed first reported a position in MRK in Q2 2013 and has held it in 42 quarters since. The position peaked at $363M in Q1 2017. 3,841 funds tracked by Wall St. Rank hold MRK as of Q2 2026.

OrbiMed held 663,400 shares of Merck worth $85.2M as of Q2 2026.
OrbiMed left its Merck share count unchanged in Q2 2026.
Merck made up 1.58% of OrbiMed's portfolio in Q2 2026, its #13 holding.
OrbiMed first reported a position in Merck in Q2 2013 and has held it in 42 quarters since.
OrbiMed's Merck position peaked at $363M in Q1 2017.
3,841 funds tracked by Wall St. Rank held Merck as of Q2 2026.

Based on OrbiMed's 13F filing for Q2 2026, filed 14 Aug 2026.